Citigroup Maintains Buy on Akero Therapeutics, Lowers Price Target to $78
Akero Therapeutics Analyst Ratings
Mineralys Therapeutics Analyst Ratings
Where Liquidia Stands With Analysts
Akero Therapeutics GAAP EPS of -$0.90 Beats by $0.12
Akero Therapeutics Q1 2025 EPS $(0.90) Beats $(0.99) Estimate, Cash, Cash Equivalents, And Short- And Long-term Marketable Securities As Of March 31, 2025, Were $1.128B, Will Be Sufficient To Fund Its Current Operating Plan Into 2028
United Therapeutics Corporation Filed A Complaint On May 9, 2025, In The U.S. District Court For The Middle District Of North Carolina Against Liquidia Alleging Infringement Of U.S. Patent No. 11,357,782.
Earnings Scheduled For May 12, 2025
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
Uncovering Potential: Mineralys Therapeutics's Earnings Preview
Xeris Biopharma Holdings Analyst Ratings
Raymond James Maintains Strong Buy on Liquidia, Raises Price Target to $29
Akero Therapeutics Publishes Results From Phase 2b SYMMETRY Trial In New England Journal of Medicine; Results Support Potential Benefit Of EFX To Elicit Fibrosis Improvement In Patients With F4 Fibrosis
Baird Maintains Outperform on Soleno Therapeutics, Raises Price Target to $105
Soleno Therapeutics Analyst Ratings
Liquidia GAAP EPS of -$0.45 Misses by $0.05, Revenue of $3.12M Misses by $0.11M
Here Are the Major Earnings Before the Open Tomorrow
Soleno Therapeutics Q1 GAAP EPS $(0.95) Misses $(0.81) Estimate
Arcutis Biotherapeutics Says ZORYVE Foam 0.3% Linked To Adverse Reactions Including Headache, Nausea, And Diarrhea, With Flammability Risk And Contraindications For Liver-Impaired Patients Highlighted In Safety Profile Under FDA Review
Liquidia Q1 2025 Earnings Preview